Lyme Disease (LD): Market View

This reports provides a data-driven overview of the current and future competitive landscape in LD Therapeutics.

In 2024 and 2029, Germany is anticipated to have the highest number of incident cases of Lyme disease, representing a large portion of global cases.

Currently, the Lyme disease market is saturated with generic drugs, and the penicillin-binding protein (PBP) inhibitor drug class dominates the approved innovator drugs currently available to treat Lyme disease.

The Lyme disease pipeline holds 23 molecules, with no asset in the pre-registration stage, one asset in Phase III, and another three assets in Phase II.

Over the past decade, 63 clinical trials have been conducted in Lyme disease. The year with the most studies initiated was 2021, followed by 2022 with nine trials and 2018 with eight trials.

During the past 26 months, four mergers and acquisitions and three strategic alliances involving companies developing Lyme disease assets were completed globally.

Scope

GlobalData's LD: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the LD Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global LD Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.